首页|血清NOX4 MUC1表达水平与Ⅲ期非小细胞肺癌患者放疗疗效及随访1年总生存率的关系研究

血清NOX4 MUC1表达水平与Ⅲ期非小细胞肺癌患者放疗疗效及随访1年总生存率的关系研究

扫码查看
目的:研究血清还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶 4(NOX4)、黏蛋白 1(MUC1)表达水平与Ⅲ期非小细胞肺癌(NSCLC)患者放疗疗效及随访1 年总生存率的关系。方法:选取2020 年4 月至2023 年3 月我院收治的102 例Ⅲ期NSCLC患者,均进行放疗干预,并在放疗前检测血清NOX4、MUC1 水平,另选择51 例健康志愿者作为对照,比较两组血清NOX4、MUC1 水平,以及放疗前不同临床特征的Ⅲ期NSCLC患者血清NOX4、MUC1 水平。根据放疗效果将Ⅲ期NSCLC 患者分为疗效良好组和疗效不佳组,对比两组血清NOX4、MUC1 水平。所有患者均进行随访,以中位血清NOX4、MUC1 水平为界,比较不同血清 NOX4、MUC1 水平的患者 1 年总生存率,并采用单因素和多因素 Cox 回归分析Ⅲ期NSCLC患者1 年生存的影响因素。结果:NSCLC 组血清 NOX4、MUC1 水平均高于对照组(P<0。05)。放疗前不同性别、年龄、体质指数(BMI)、肿瘤位置、肿瘤最大直径、病理分型的Ⅲ期 NSCLC 患者血清NOX4、MUC1 水平比较差异均无统计学意义(P>0。05)。本次102 例Ⅲ期NSCLC患者放疗结果显示,疗效良好组例数为55 例,疗效不佳组例数为47 例。疗效良好组血清 NOX4、MUC1 水平低于疗效不佳组(P<0。05)。高水平NOX4 组患者1 年总生存率低于低水平NOX4 组(P<0。05),高水平MUC1 组患者1年总生存率低于低水平 MUC1 组(P<0。05)。单因素和多因素 Cox 回归分析结果显示,血清 NOX4、MUC1 水平是Ⅲ期NSCLC患者放疗后 1 年生存的影响因素(P<0。05)。结论:Ⅲ期 NSCLC 患者血清NOX4、MUC1 表达水平与其放疗疗效及随访 1 年总生存率有关,检测血清 NOX4、MUC1 水平有利于辅助评估患者放疗疗效和早期预后生存情况。
Relationship between Expression Levels of Serum NOX4 and MUC1 with Radiotherapy Efficacy and 1-Year Overall Survival Rate in Patients with Stage Ⅲ Non-Small Cell Lung Cancer
Objective:To study the relationship between expression levels of serum nicotinamide adenine dinucleotide phosphate(NADPH)oxidase 4(NOX4)and mucin 1(MUC1)with radiotherapy efficacy and o-verall survival rate of 1-year follow-up in patients with stage Ⅲ non-small cell lung cancer(NSCLC).Methods:Totally 102 patients with stage Ⅲ NSCLC in the hospital from April 2020 to March 2023 were se-lected for radiotherapy intervention,and serum NOX4 and MUC1 levels were detected before radiotherapy.Another 51 healthy volunteers were selected as controls.Before radiotherapy,the inter-group levels of serum NOX4 and MUC1 were compared,and the intra-class levels of serum NOX4 and MUC1 in patients stage ⅢNSCLC with different clinical characteristics were assessed.According to the radiotherapy effect,patients with stage Ⅲ NSCLC were divided into good efficacy group and poor efficacy group,and the levels of serum NOX4 and MUC1 were compared after radiotherapy.All patients were followed up,and the 1-year overall survival rates of different patients were compared using the median levels of serum NOX4 and MUC1.Univariate and multivariate Cox regression analyses were used to analyze the influencing factors of 1-year survival rate in pa-tients with stage Ⅲ NSCLC.Results:The levels of serum NOX4 and MUC1 in NSCLC group were significant-ly higher than those in control group(P<0.05).There were no statistical differences in serum NOX4 and MUC1 levels among stage Ⅲ NSCLC patients with different genders,ages,body mass index(BMI)values,tumor locations,maximum tumor diameters and pathological types before radiotherapy(P>0.05).Among 102 patients with stage Ⅲ NSCLC,the radiotherapy results showed that 55 patients were in the good efficacy group and 47 patients were in the poor efficacy group.Serum levels of NOX4 and MUC1 in good efficacy group were significantly lower than those in poor efficacy group(P<0.05).The 1-year overall survival rate in high-level NOX4 group was significantly lower than that in low-level NOX4 group(P<0.05),which in high-level MUC1 group was significantly lower than that in low-level MUC1 group(P<0.05).Univariate and multivari-ate Cox regression analyses showed that serum NOX4 and MUC1 levels were the influencing factors of 1-year survival rate in patients with stage Ⅲ NSCLC after radiotherapy(P<0.05).Conclusion:The expression lev-els of serum NOX4 and MUC1 in patients with stage Ⅲ NSCLC are related to the radiotherapy efficacy and o-verall survival rate after one year of follow-up.The detection of serum NOX4 and MUC1 levels is helpful to e-valuate the radiotherapy efficacy and early prognosis survival.

Non-small cell lung cancerStage ⅢRadiotherapyReduced nicotinamide ade-nine dinucleotide phosphate oxidase 4Mucin 1

陆珏、蔡梦娇、张莹冰

展开 >

西安交通大学医学院第一附属医院肿瘤放射治疗科,陕西 西安 710061

非小细胞肺癌 Ⅲ期 放疗 还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶4 黏蛋白1

2024

河北医学
河北省医学会

河北医学

CSTPCD
影响因子:1.915
ISSN:1006-6233
年,卷(期):2024.30(12)